Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Binimetinib with Chemotherapy in KRAS-mutant NSCLC
NCT02964689Phase 1Completed
- Sponsor
- Swiss Group for Clinical Cancer Research
- Start
- Apr 2017
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of binimetinib in non-small cell lung cancer (NSCLC), sponsored by Swiss Group for Clinical Cancer Research. Primary endpoint: Dose-limiting toxicities at 21 days. Started Apr 2017; status: completed.
02
Drugs
binimetinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02964689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02964689.